Frazier Life Sciences Management, L.P. Travere Therapeutics, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.9 Billion
- Q2 2025
A detailed history of Frazier Life Sciences Management, L.P. transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 1,002,092 shares of TVTX stock, worth $17.4 Million. This represents 0.78% of its overall portfolio holdings.
Number of Shares
1,002,092Holding current value
$17.4 Million% of portfolio
0.78%Shares
1 transactions
Others Institutions Holding TVTX
# of Institutions
231Shares Held
102MCall Options Held
1.73MPut Options Held
401K-
Janus Henderson Group PLC London, X09.54MShares$166 Million0.07% of portfolio
-
Armistice Capital, LLC New York, NY8.88MShares$155 Million2.3% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$133 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.99MShares$104 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C35.1MShares$88.7 Million0.1% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.12B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...